Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 5/1999

01-01-1999 | ORIGINAL ARTICLE

Organ-specific pancreatic tumor growth properties and tumor immunity

Authors: Keita Morikane, Richard M. Tempero, Connie L. Sivinski, Mitsuharu Nomoto, Michelle L. Van Lith, Tetsuichiro Muto, Michael A. Hollingsworth

Published in: Cancer Immunology, Immunotherapy | Issue 5/1999

Login to get access
Metadata
Title
Organ-specific pancreatic tumor growth properties and tumor immunity
Authors
Keita Morikane
Richard M. Tempero
Connie L. Sivinski
Mitsuharu Nomoto
Michelle L. Van Lith
Tetsuichiro Muto
Michael A. Hollingsworth
Publication date
01-01-1999
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 5/1999
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050533

Other articles of this Issue 5/1999

Cancer Immunology, Immunotherapy 5/1999 Go to the issue

ORIGINAL ARTICLE

Isolation of MUC1-primed B lymphocytes from tumour-draining lymph nodes by immunomagnetic beads

ORIGINAL ARTICLE

A tandem repeat of MUC1 core protein induces a weak in vitro immune response in human B cells

ORIGINAL ARTICLE

In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors

ORIGINAL ARTICLE

Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes

REVIEW

Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2

ORIGINAL ARTICLE

Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with the B7.1-transduced MCA205 cell line
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits